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Abstract
Natural products represent a rich reservoir of potential small chemical molecules
exhibiting anti-proliferative and chemopreventive properties. Here, we show that
treatment of pancreatic ductal adenocarcinoma (PDAC) cells (PANC-1, MiaPaCa-
2) with the isoquinoline alkaloid berberine (0.3–6 mM) inhibited DNA synthesis and
proliferation of these cells and delay the progression of their cell cycle in G1.
Berberine treatment also reduced (by 70%) the growth of MiaPaCa-2 cell growth
when implanted into the flanks of nu/nu mice. Mechanistic studies revealed that
berberine decreased mitochondrial membrane potential and intracellular ATP levels
and induced potent AMPK activation, as shown by phosphorylation of AMPK a
subunit at Thr-172 and acetyl-CoA carboxylase (ACC) at Ser79. Furthermore,
berberine dose-dependently inhibited mTORC1 (phosphorylation of S6K at Thr389
and S6 at Ser240/244) and ERK activation in PDAC cells stimulated by insulin and
neurotensin or fetal bovine serum. Knockdown of a1 and a2 catalytic subunit
expression of AMPK reversed the inhibitory effect produced by treatment with low
concentrations of berberine on mTORC1, ERK and DNA synthesis in PDAC cells.
However, at higher concentrations, berberine inhibited mitogenic signaling
(mTORC1 and ERK) and DNA synthesis through an AMPK-independent
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mechanism. Similar results were obtained with metformin used at doses that
induced either modest or pronounced reductions in intracellular ATP levels, which
were virtually identical to the decreases in ATP levels obtained in response to
berberine. We propose that berberine and metformin inhibit mitogenic signaling in
PDAC cells through dose-dependent AMPK-dependent and independent
pathways.
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, with overall 5-
year survival rate of only 6% [1]. The incidence of this disease in the US is
estimated to increase to more than 44,000 new cases in 2014 and is now the fourth
leading cause of cancer mortality in both men and women [2]. Total deaths due to
PDAC are projected to increase dramatically to become the second leading cause
of cancer-related deaths before 2030 [1] As the current therapies offer very limited
survival benefits, novel strategies to treat and prevent this aggressive disease are
urgently required [3].
G protein-coupled receptors (GPCRs) and their cognate agonists are
increasingly implicated as autocrine/paracrine growth factors for multiple solid
tumors, including small cell lung cancer, colon, prostate, breast and pancreas [4–
8]. We showed that pancreatic cancer cell lines express multiple GPCRs [9] and a
variety of GPCR agonists, including neurotensin, angiotensin II and bradykinin,
stimulated DNA synthesis in pancreatic cancer cell lines, including PANC-1 and
MiaPaca-2 [9–12]. Furthermore, a broad-spectrum GPCR antagonist [13, 14],
inhibited the growth of pancreatic cancer cells either in vitro or xenografted into
nu/nu mice [15]. Other studies demonstrated increased expression of GPCRs in
pancreatic cancer tissues [16–19]. Subsequently, we identified positive crosstalk
between insulin/IGFI receptors and GPCR signaling systems in pancreatic cancer
cells, leading to mTORC1 signaling and ERK activation, and synergistic
stimulation of DNA synthesis and cell proliferation [20–22]. These findings
assume an added importance in view of the large number of epidemiological
studies linking long standing type-2 diabetes mellitus (T2DM), obesity and
metabolic syndrome, characterized by peripheral insulin resistance and compen-
satory overproduction of insulin, with increased risk for developing pancreatic
cancer [23–32].
The biguanide metformin (1,1-dimethylbiguanide hydrochloride) derived from
galegine, a phytochemical from Galega officinalis, is the most widely prescribed
drug for treatment of T2DM, worldwide [33, 34]. Systemically, metformin lowers
blood glucose levels through reduced hepatic gluconeogenesis, increases glucose
uptake in skeletal muscles and adipose tissue [34, 35] and reduces the circulating
levels of insulin and IGF-1 [36, 37]. At the cellular level, metformin indirectly
stimulates AMP–activated protein kinase (AMPK) activation [38] via inhibition
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of mitochondrial function, though other mechanisms of metformin action have
been also suggested at high doses [39]. Major downstream targets of AMPK
include TSC2 and Raptor [40–43]. The AMPK-mediated phosphorylation of these
targets inhibits mTOR complex 1 (mTORC1) activity in a variety of cell types,
including PDAC cells [44, 45] and disrupts positive crosstalk between insulin/IGFI
receptors and GPCR signaling systems [21, 46]. Interestingly, a number of
observational studies suggest that metformin reduces incidence and improved
prognosis of a variety of cancers in patients with T2DM [47, 48], though this this
conclusion is under scrutiny [49]. In the setting of PDAC, diabetic patients who
had received metformin appear to have lower adjusted incidence and better
survival compared with those who had not taken metformin or used other anti-
diabetic agents [47, 50–52]. We hypothesized that structurally unrelated natural or
synthetic compounds that interfere with mitochondrial-mediated ATP synthesis
and target mTORC1 and ERK pathways, could provide novel anti-PDAC agents.
Natural products represent a rich reservoir of potential small chemical
molecules exhibiting diverse pharmacological properties. The isoquinoline
alkaloid berberine [53–55], a phytochemical extracted from a variety of medicinal
plants, including plants of the Berberis species induces multiple biological effects,
including anti-obesity, anti-diabetic, anti-cancer and calorie-restriction effects
[55–62]. The cellular mechanism(s) involved, however, remains incompletely
understood. Berberine has been reported to inhibit mitochondrial function and
induce AMPK activation [63] but other mechanisms of action of this alkaloid
have been proposed when added at high concentrations [64, 65]. Despite its
potential clinical implications, there is no understanding of the precise
mechanism(s) by which berberine inhibits the proliferation of cancer cells and it is
not known whether this agent has any direct effect on signaling and proliferation
of PDAC cells harboring KRAS mutations, characteristic of .90% of ductal
pancreatic carcinomas.
In this study, we show that berberine inhibits DNA synthesis, cell cycle
progression and proliferation in PANC-1 and MiaPaca-2 pancreatic cancer cells.
Furthermore, berberine administration inhibits the growth of PDAC tumor
xenografts in vivo as effectively as metformin. In mechanistic studies, we
demonstrate that berberine, like metformin decreases mitochondrial membrane
potential and ATP levels and concomitantly induces AMPK activation. Based on
results using siRNA-mediated knockdown of AMPK, we propose that the
inhibitory effects of berberine and metformin are mediated through AMPK-
dependent and AMPK-independent pathways depending on the dose of each
agent. This conclusion provides a plausible explanation for apparently contra-
dictory reports on the role of AMPK in the mechanism of action of berberine and
metformin in other model systems.
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Materials and Methods
Chemicals and Reagents
Dulbecco’s modified Eagle Medium (DMEM) was obtained from Invitrogen
(Carlsbad, CA). Neurotensin, insulin, berberine and metformin were obtained
from Sigma Chemical (St. Louis, MO). All antibodies were purchased from Cell
Signaling Technology (Danvers, MA). Horseradish peroxidase-conjugated anti-
rabbit IgG and anti-mouse IgG were from GE Healthcare Bio-Sciences Corp
(Piscataway, NJ). All other reagents were of the highest grade available.
Cells and Culture Conditions
The human pancreatic cancer cell lines PANC-1 and MiaPaCa-2 were obtained
from the American Type Culture Collection (ATCC, Manassas, VA). These cell
lines were chosen because they harbor mutations typical of human pancreatic
cancer [66], including activating mutations in KRAS, TP53 (encoding the p53
protein) and CDKN2A (also known as p16 or p16INK4a). Indeed, there is an
excellent correlation between point mutation frequencies in PDAC cell lines and
primary tumors [67]. Cells were grown in DMEM supplemented with 2 mM
glutamine, 1 mM Na-pyruvate, 100 units/mL penicillin, and 100 mg/mL
streptomycin and 10% fetal bovine serum (FBS) at 37 C˚ in a humidified
atmosphere containing 10% CO2. In the experiments, the glucose concentration
in DMEM was adjusted to 5 mM, a physiological level in human serum.
[3H]-Thymidine Incorporation into DNA
PANC-1 and MiaPaCa-2 cells (16105) were plated and grown in 3.5 cm tissue
culture plates for 5 days in DMEM supplemented with 10% FBS. The cells were
washed twice and incubated for 24 h with DMEM containing 5 mM glucose and
1% FBS. To start the experiment, fresh medium containing the specified
concentration of agonist and/or inhibitor was added after washing twice with
DMEM (4 cultures used for each condition), and then the cells were incubated for
17 h and then pulse labeled for 6 h with [3H]-thymidine (0.25 mCi/ml). The cells
were fixed with 5% trichloroacetic acid and washed twice with ethanol. Acid-
insoluble pools were dissolved in 0.1 N NaOH with 1% SDS and the radioactivity
incorporated was counted in a liquid scintillation counter.
Mitochondrial Membrane Potential
The cell-permeable JC-1 dye (Invitrogen), which exhibits potential-dependent
accumulation in the mitochondria, was used as an indicator of mitochondrial
membrane potential. Following treatment without or with berberine or
metformin, JC-1 was added to cultures of PANC-1 or MIA PaCa-2 cells at 1 mg/
ml for 30 min. Then, the media was exchanged for Hanks Buffered Saline
Solution containing 5 mM glucose and cells were immediately imaged using
rhodamine and fluorescein optics. Images were stored from several visual fields.
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The histogram analysis feature of Photoshop (Adobe) was used to measure the
average red and average green fluorescence intensity from about 50 cells in a visual
field. At least 5 independent fields were measured in each condition. The results
are expressed as an average ratio of red/green florescent intensity in a single visual
field (mean ¡ SEM). The ratio of red/green fluorescence intensity indicates
mitochondrial membrane potential with a decreased ratio indicating a loss of
potential.
ATP Determination
PANC-1 and MiaPaCa-2 cells (56104) were plated and grown in 24 well culture
plates for 5 days in DMEM and 10% FBS. The cells were then incubated for 24 h
with DMEM containing 5 mM glucose and 1% FBS. The cells were washed twice
with DMEM containing 5 mM glucose and incubated in serum-free medium for
17 h in the absence or presence of berberine or metformin. ATP levels were
determined using the firefly luciferase/D-luciferin ATP determination Kit
according to the manufacturer’s protocol (Life Technologies Grand Island, NY).
Knockdown of AMPK levels via siRNA transfection
Silencer Select siRNAs were purchased from Life Technologies (Grand Island, NY)
and designed to target either human AMPKa1 or human AMPKa2. Cells were
transfected using the reverse transfection method. Either Silencer Select non-
targeting negative control or a mixture of 10 nM AMPKa1 and 10 nM AMPKa2
siRNA (AMPKa1, a2 siRNA) were mixed with Lipofectamine RNAi MAX (Life
Technologies Grand Island, NY) according to the manufacturer’s protocol and
added to 24 well plates. PANC-1 cells were then plated on top of the siRNA/
Lipofectamine RNAiMAX complex at a density of 105 cells/well.in DMEM
containing 5 mM glucose and 10% FBS. Three days after transfection the cells
were incubated for 24 h with DMEM containing 5 mM glucose and 1% FBS. The
cells were washed twice with DMEM containing 5 mM glucose and incubated in
serum-free medium for 17 h in the absence or presence of berberine or metformin
and then treated as described in the corresponding figure legends.
Flow cytometric/cell cycle analysis
The proportion of cells in the G0/G1, S, G2, and M phases of the cell cycle was
determined by flow cytometric analysis. PANC-1 cells (26104 cells) were seeded
in DMEM containing 2.5% FBS. After 24 h the cultures were treated without or
with berberine in medium containing 2.5% FBS for 3 days. Cells were then
harvested by trypsinization, centrifuged at 1,000 g for 5 min and resuspended in a
final concentration of 106 cells/ml in hypotonic propidium iodide (PI) solution
containing 0.1% Sodium citrate, 0.3% Trixon-X 100, 0.01% PI and 0.002%
Ribonuclease A. Cells were incubated in 4 C˚ for 30 min and analyzed on a
FACScan (Becton-Dickinson, Franklin Lakes, NJ) using the software CELLQuest.
One hundred thousand cells were collected for each sample. Excitation occurred
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at 488 nm and data was collected using the FL2 channel and analyzed using FCS
ExpressV3.
Western Blot Analysis
Confluent cultures of PANC-1 or Mia PaCa-2 cells grown on 3.5 cm dishes were
washed and then incubated for 24 h with DMEM containing 5 mM glucose and
1% FBS. The cells were then washed twice with DMEM containing 5 mM glucose
and incubated in serum-free medium in the absence or presence of berberine,
metformin or A-769662, as described in the individual experiments. The cultures
were then directly lysed in 26 SDS-PAGE sample buffer [200 mM Tris-HCl
(pH 6.8), 2 mM EDTA, 0.1 M Na3VO4, 6% SDS, 10% glycerol, and 4% 2-
mercaptoethanol], followed by SDS-PAGE on 10% gels and transfer to
Immobilon-P membranes (Millipore, Billerica, MA). Western blots were then
performed on membranes incubated overnight with the specified antibodies in
phosphate-buffered saline (PBS) containing 0.1% Tween-20. The immunoreactive
bands were detected with ECL (enhanced chemiluminescence) reagents (GE
Healthcare Bio-Sciences Corp, Piscataway, NJ). The antibodies used detected the
phosphorylated state of S6K at Thr389, S6 at Ser240/244 and ERK1/2 at Thr202 and
Tyr204, AMPKa at Thr172, ACC at Ser79 and Raptor at Ser792. In addition, the total
level of these proteins was also evaluated. Routinely, the membranes used with the
phospho-specific antibodies were stripped and re-blotted with the antibodies that
detect the total level of the corresponding protein. Occasionally, stripping and re-
blotting of the same membrane was not satisfactory for obtaining both loading
and expression controls. In these cases, we used a separate blot for assessing total
protein expression and immunoblotted the original membrane for other proteins
(e.g. actin, S6K, S6, ERK) that migrate at a different position in the original gel for
verifying equal loading.
Cell Proliferation
Cultures of PANC-1 and MiaPaCa-2 cells, 3–5 days after passage, were washed
and suspended in DMEM containing 5 mM glucose. Cells were then
disaggregated by two passes through a 19-guage needle into an essentially single-
cell suspension as judged by microscopy. Cell number was determined using a
Coulter Counter, and 26104 cells were seeded in 35 mm tissue culture plates in
DMEM containing 5 mM glucose and 10% FBS. After 24 h of incubation, the
medium was removed and the cultures shifted to DMEM containing 5 mM
glucose without or with 3% FBS. The cultures were then incubated in a
humidified atmosphere containing 10% CO2 at 37 C˚ for 4 days and the total cell
count was determined from a minimum of four dishes per condition using a
Coulter counter, after cell clumps were disaggregated by passing the cell
suspension ten times through a 19- and subsequently a 21-gauge needle.
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Mice xenografts
Early-passage MiaPaCa-2 cells were harvested, and 26106 cells were implanted
into the right flanks of male nu/nu mice. The male nu/nu mice were maintained in
specific pathogen-free facility at University of California at Los Angeles (UCLA).
The UCLA Chancellor’s Animal Research Committee approved all the animal
experiments. The animals were randomized into control and treated groups (10
mice per group) and were given punched ear tags to allow identification.
Treatment was initiated when the tumors reached a mean diameter of 2 mm, and
the 1st day of treatment in both cases was designated as day 0. For injection into
animals, metformin (250 mg/Kg), berberine (5 mg/kg) or vehicle (control) was
given intraperitoneally once daily intraperitoneally (50 mL/mouse). Tumor
volume (V) was measured by external caliper every 4 days and it was calculated as
V50.52 (length 6 width2). At the end of the experiment, the tumors were
dissected weighted and measured. The volume of the excised tumors was
calculated as V50.52 (length 6 width 6 depth).
Statistical analysis
Values are means ¡ SE. Differences between groups were analyzed with the
unpaired Student’s t-test.
Results
Berberine inhibits DNA synthesis, cell cycle progression and cell
proliferation in PDAC cells
Initially, we determined the effect of the isoquinoline alkaloid berberine on DNA
synthesis in PANC-1 and MiaPaCa-2 cells, which have been used extensively as
models of PDAC cells. Cultures of these cells grown in medium containing 10%
fetal bovine serum were washed and transferred to serum-free medium for 24 h.
Then, the cells were switched to medium containing a physiological concentration
of glucose (5 mM), increasing doses of berberine and a combination of insulin
(10 ng/ml) and the GPCR agonist neurotensin (5 nM) to elicit potent mitogenic
crosstalk signaling [20, 21, 46]. Treatment with berberine inhibited the stimulation
of DNA synthesis in a dose-dependent manner in both PANC-1 and MiaPaCa-2
cells. At a concentration of 3 mM, berberine inhibited DNA synthesis by 82% in
MiaPaCa-2 cells and by 76% in PANC-1 cells. The incorporation of [3H]-
thymidine was blocked by 97% in MiaPaCa-2 cells and by 94% in PANC-1 cells in
response to 6 mM berberine (Fig. 1 A).
The assays of [3H]-thymidine incorporation were complemented by flow
cytometric analysis to determine the proportion of PDAC cells in the various
phases of the cell cycle. As shown in Fig. 1B, exposure of PANC-1 cells to
berberine (1.5–3 mM) induced a marked increase in the proportion of cells in G1
(from 61¡0.2% in cells with FBS to 79¡2% in cells with FBS and berberine) and
a corresponding decrease in the proportion of cells that were in S and G2/M phase
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Fig. 1. Berberine inhibits DNA synthesis, cell cycle progression and proliferation in PANC-1 and Mia PaCa-2 cells. A, Mia PaCa-2 or PANC-1 cells
were incubated without (open bars) or with 5 nM neurotensin and 10 ng/ml insulin (closed bars) in the presence of increasing concentration of berberine for
17 h at 37˚C prior to the addition of [3H]-thymidine for 6 h. The radioactivity incorporated into acid-insoluble pools was measured in a scintillation counter, as
described in ‘‘Materials and Methods. The values shown are the mean¡ SEM obtained in 3 independent experiments; B, PANC-1 cells were treated without
(control) or with berberine at 1.5 mM or 3 mM in medium containing 2.5% FBS for 3 days (indicated by cont., FBS, FBS +1.5 Ber and FBS +3 Ber). Cell cycle
Berberine and Metformin Inhibit Mitogenic Signaling in PDAC Cells
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of the cell cycle (from 36¡0.1% to 19¡0.7%). These results indicate that
berberine delays the progression of the PDAC cell cycle at G1.
We next examined the effect of berberine on the proliferation of pancreatic
cancer cells. Single cell suspensions of either PANC-1 or MiaPaCa-2 cells were
plated and incubated in media supplemented without or with 3% FBS in the
absence or presence of 3 mM berberine. Treatment with berberine markedly
inhibited proliferation in both PDAC cells (Fig. 1C) without affecting cell viability
at the doses tested (results not shown). Taken together, the results in Fig. 1
demonstrate that berberine inhibits DNA synthesis, cell cycle progression and
proliferation in pancreatic cancer cells.
Berberine and metformin inhibit the growth of a PDAC xenograft in
nude mice
Given our results showing inhibitory effects of berberine on PDAC cell
proliferation in vitro, we subsequently determined whether this compound
inhibits pancreatic cancer growth in vivo using MiaPaca-2 tumor xenografts in
nude mice. The xenografts were derived by implantation of 26106 cells into the
right flanks of male nu/nu mice. The animals were randomized into control and
berberine-treated groups (10 mice per group). Berberine was given once daily
intraperitoneally at 5 mg/kg for the duration of the experiment. As shown in
Fig. 2, administration of berberine decreased the growth of MiaPaca-2 cells
xenografted in nude mice by 70%. The tumor volumes at the end of the
experiment (day 29) were 781 mm3 in the control and 240 mm3 in the berberine
treated group (p,0.001). The dose of berberine used (5 mg/kg) is 12-fold lower
than the LD50, based on preliminary range-finding studies and previous work
published by others [53, 68, 69]. Berberine was well tolerated and did not
significantly affect the weight of the mice during the treatment (Fig. 2, B). The
inhibitory effect of berberine was comparable to that induced by metformin given
at 250 mg/Kg (Fig. 2), a dose that induces maximal inhibitory effect on PDAC
tumor growth [70]. Indeed, the curves corresponding to the growth of MiaPaca-2
xenografts in mice treated with berberine or metformin were virtually super-
imposable during the first 24 days (Fig. 2, A). At day 29, metformin was slightly
more effective than berberine as assessed by tumor volume (p,0.05) but the
effects did not reach statistical significance (p.0.07) when scored by tumor
weight (Fig. 2, B). These results indicate that berberine inhibits the growth of
human pancreatic cancer cells xenografted into nude mice with efficacy
comparable to that achieved by a maximal dose of metformin.
was analyzed by PI-staining and flow cytometry. Similar results were obtained in 3 independent experiments. C, Single-cell suspension of Mia PaCa-2 or
PANC-1 cells were plated on tissue culture dishes at a density of 26104 cells per dish. After 24 h of incubation the medium was removed and the cultures
shifted to medium without or with 3% FBS in the absence (open bars) or presence (closed bars) of 3 mM berberine. The cultures were incubated for 4 days
as described in ‘‘Materials and Methods’’. Cell count was determined from 4 to 6 replicate plates per condition using a Coulter Counter. Results are
presented as mean ¡ SEM of 3 biological replicates.
doi:10.1371/journal.pone.0114573.g001
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Berberine induces mitochondrial membrane depolarization,
reduces the levels of ATP and stimulates AMPK in pancreatic
cancer cells
Having established that berberine inhibits PDAC cell proliferation in vitro and
in vivo, we next explored the mechanisms involved. In other cell types, berberine
is thought to inhibit complex I of the mitochondrial respiratory chain [71, 72],
resulting in reduced ATP synthesis and concomitant increase in cellular AMP and
ADP which are potent allosteric activators of AMPK [73–75]. Because it is not
known whether berberine has any effect on mitochondrial function in pancreatic
cancer cells, we initially examined whether this phytochemical interferes with
mitochondrial membrane potential in these cells. Cultures of MiaPaCa-2 and
PANC-1 cells were incubated in the absence or presence of 3 mM berberine or
1 mM metformin, included for comparison. Then, mitochondrial membrane
potential, a key component driving ATP synthesis, was assessed using the
mitochondrial-specific fluorescent probe JC-1 [76]. As shown in Fig. 3 A,
berberine caused a significant fall in mitochondrial membrane potential in
MiaPaCa-2 and PANC-1 cells. The effect was comparable to that induced by
metformin (Fig. 3 A). These results indicate that berberine, like metformin,
targets mitochondrial function in PDAC cells. Accordingly, exposure to increasing
concentrations of berberine or metformin produced a marked dose-dependent
decrease in the intracellular ATP levels in both PANC-1 and MiaPaCa- 2 cells
(Fig. 3 B).
Fig. 2. Berberine inhibits the growth of MiaPaCa-2 tumor xenografts as effectively as metformin. Xenografts of MiaPaca-2 were generated by
implantation of 26106 cells into the right flanks of male nu/nu mice. When the tumors reached a mean diameter of 2 mm the animals were randomized into
control and treated groups (10 mice per group). Berberine was given once daily intraperitoneally at 5 mg/kg for the duration of the experiment. For
comparison, metformin was given intraperitoneally to another group of mice at 250 mg/kg. The 1st day of treatment was designated as day 0. Control
animals received an equivalent volume of saline. A, Tumor volumes were measured every 4 days as described in ‘‘Materials and Methods’’. At the end of the
experiment (day 29, the tumors were removed, weighted and measured and tumor volumes estimated as V50.52 (length6 width6 depth). The results are
shown in panel B (mean¡ SEM). Treatment of mice with berberine significantly reduced the volume and weight of the tumors as compared with the tumors
from the control group (p,0.001), as indicated. A similar inhibition of tumor growth was obtained by administration of metformin (p,0.001). The curves
corresponding to the growth of MiaPaca-2 xenografts in mice treated with berberine or metformin were superimposable during the first 24 days. At day 29,
metformin was slightly more effective than berberine as assessed by tumor volume (p,0.05) but the difference of the effects between these drugs did not
reach statistical significance (p.0.07) when scored by tumor weight (Fig. 2, B). At the concentrations used, berberine and metformin were well tolerated
with no apparent toxicity based on body weight changes.
doi:10.1371/journal.pone.0114573.g002
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We next determined whether berberine stimulates AMPK activity within intact
MiaPaCa-2 and PANC-1 cells. Lysates of these cells were analyzed by
immunoblotting using antibodies that detect the phosphorylated state of acetyl-
CoA carboxylase (ACC) at Ser79, a residue directly phosphorylated by AMPK and
used as a biomarker of AMPK activity within intact cells [75]. Treatment with
berberine induced a marked increase in the phosphorylation of ACC at Ser79 in a
dose-dependent manner in both PANC-1 and MiaPaCa-2 cells (Fig. 3, C;
quantification in Fig. 3 D). Maximal effect was elicited at doses .2 mM in both
PDAC cells (Fig. 3 D). Furthermore, treatment of MiaPaCa-2 or PANC-1 cells
with berberine induced a striking increase in the phosphorylation of AMPK at
Fig. 3. Berberine and metformin induce mitochondrial membrane depolarization, reduce ATP levels and activate AMPK in PDAC cells. A, Cultures
of PANC-1 and MiaPaca-2 cells were incubated in the absence or in the presence of 3 mM berberine (Berb) or 1 mM metformin (Met) for 17 h in DMEM
containing 5 mM glucose. The change in mitochondrial membrane potential was measured using the mitochondrial membrane potential indicator JC-1. The
results are expressed as an average ratio of red/green florescent intensity in a single visual field (mean ¡ SEM). At least 5 fields were studied in each
condition. P values were determined using the t-test (SigmaPlot 12.); *p,0.002. B, Cultures of PANC-1 and MiaPaca-2 cells were incubated in the absence
or in the presence of berberine or metformin at the indicated concentrations for 17 h in DMEM containing 5 mM glucose and 2.5% FBS. C, Cultures of
PANC-1 (upper panels) and MiaPaCa-2 (lower panels) were incubated in the absence or in the presence of berberine at the indicated doses for 17 h. Then,
the cells were stimulated for 1 h with 5 nM neurotensin and 10 ng/ml insulin and lysed with 2X SDS-PAGE sample buffer. The samples were analyzed by
SDS-PAGE and immunoblotting with antibodies that detect the phosphorylated state of Acetyl-CoA Carboxylase (ACC) at Ser79. Western blotting for actin
was used to verify equal loading in the same membrane and a separate gel confirmed that expression of total ACC protein was not changed by any of the
treatments. D, Quantification was performed using Multi Gauge V3.0. The values represent the mean¡ SEM; n53, fold increase in ACC phosphorylation at
Ser79. Inset, phosphorylated state of AMPK at Thr172 at the indicated concentrations of berberine (mM).
doi:10.1371/journal.pone.0114573.g003
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Thr172, the residue in the kinase domain of the catalytic subunit (a) of AMPK
critical for activation (Inserts in Fig. 3 D). Collectively, the results demonstrate
that berberine decreases mitochondrial membrane potential and lowers
intracellular levels of ATP thereby stimulating AMPK activity in PDAC cells
cultured in medium containing a physiological concentration of glucose (5 mM).
Berberine inhibits mTORC1 and ERK activation in PDAC cells
The activation of the PI3K/Akt/mTORC1 and MEK/ERK pathways plays a pivotal
role in stimulating DNA synthesis, cell cycle progression and proliferation of
PDAC cells and are negatively regulated by AMPK [21]. Consequently, we
determined whether berberine inhibits mTORC1 and ERK activation in PDAC
cells. Cultures of MiaPaCa-2 cells were treated with increasing doses of berberine
and then stimulated with a combination of insulin and neurotensin to elicit
positive crosstalk (Fig. 4). Lysates of these cells were analyzed by immunoblotting
using antibodies that detect the phosphorylated state of S6K at Thr389, a residue
directly phosphorylated by mTORC1, using Western blot analysis with antibodies
that specifically detect the phosphorylated state of this residue. To corroborate
that phosphorylation of S6K at Thr389 reflects its activation within PDAC cells, we
examined the phosphorylation of the 40S ribosomal protein subunit S6, a
downstream target of S6K [77]. As shown in Fig. 4 A, stimulation with insulin
and neurotensin induced a marked increase in mTORC1 activity, as scored by
phosphorylation of S6K and S6 protein (pS6K and pS6). Treatment with
berberine prevented mTORC1 activation in a dose-dependent manner (Fig. 4A;
quantification in Fig. 4 B).
Given the pivotal importance of the RAS/MEK/ERK pathway in PDAC
development and maintenance, we also analyzed the effect of increasing
concentrations of berberine on ERK activation by detecting ERK phosphorylated
on Thr202 and Tyr204. The results in Fig. 4 A, B demonstrated that berberine
prevented ERK activation in MiaPaCa-2 cells, in a dose-dependent manner. The
doses of berberine that inhibited ERK activation were similar to those that blunted
mTORC1 activation and produced AMPK activation.
Similar to the results obtained with MiaPaCa-2 cells, berberine inhibited
mTORC1 and ERK activation by insulin and neurotensin in a dose-dependent
manner in PANC-1 cells (Fig. 4 C; quantification in Fig. 4 D). We also found that
berberine inhibited mTORC1 and ERK signaling in PANC-1 cells stimulated with
FBS instead of insulin and neurotensin (S1 Figure). The results presented so far
demonstrate that berberine inhibited mTORC1, ERK and cell proliferation in
PDAC cells at doses that reduced the intracellular ATP levels and induced robust
AMPK activation.
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Fig. 4. Berberine inhibits mTORC1 signaling and ERK activation in PDAC cells. Cultures of MiaPaCa-2
(Panels A and B) or PANC-1 cells (panels C and D) were incubated in the absence or in the presence of
increasing concentrations of berberine. Then, the cells were stimulated for 1 h with 5 nM neurotensin and
10 ng/ml insulin and lysed with 2X SDS-PAGE sample buffer. The samples were analyzed by SDS-PAGE and
immunoblotting with antibodies that detect the phosphorylated state of S6K at Thr389, S6 at Ser240/244, and
ERK at Thr202 and Tyr204. Immunoblotting with total S6K, S6 and ERK was used to verify equal gel loading.
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Knockdown of the a subunits of AMPK reverses inhibition of
mTORC1, ERK and DNA synthesis induced by low doses of
berberine or metformin: evidence for AMPK-dependent and
AMPK-independent mechanisms
In order to determine the role of AMPK in mediating berberine-induced
inhibition of PDAC cell signaling and proliferation, we used short interfering
RNA (siRNA), which effectively (.90%) knockdown the protein expression of
both a1 and a2 catalytic subunits of AMPK, as compared with cells transfected
with non-targeting siRNA (Fig. 5, A). Accordingly, berberine-induced increases
in the phosphorylation of ACC at Ser79 and Raptor at Ser792, were blunted in the
cells treated with siRNA targeting the a1 and a2 catalytic subunits of AMPK
(Fig. 5, A; quantification in Fig. 5, B). The salient feature in Fig. 5, A is that
knockdown of AMPK prevented the inhibitory effect produced by treatment with
low doses of berberine (,3 mM) on the stimulation of mTORC1 (scored by
phosphorylation of S6K at Thr389 and of its substrate S6) and ERK activation in
PDAC cells. In contrast, knockdown of AMPK expression prevented only partially
the inhibitory effect berberine added at 6 mM. It was conceivable that the
inhibitory effect of berberine at the high concentration was due to incomplete
elimination of AMPK after silencing. However, the dose-response relationships
presented in Figs. 2 and 5 argue against this possibility. Specifically, ACC
phosphorylation at Ser79 reached a plateau in cells challenged with berberine at
doses 2–6 mM (Fig. 2) or 3–6 mM (Fig. 5B). The faint ACC phosphorylation
remaining after knockdown of AMPK followed a similar dose-response
relationship, i.e. phosphorylation was increased only slightly and to same level by
either 3 mM or 6 mM berberine in AMPK-depleted cells (Fig. 5). Furthermore, the
marked increase in Raptor phosphorylation at Ser792 in response to berberine at
6 mM was also blocked by knockdown of AMPK expression (Fig. 5A;
quantification in Fig. 5, B). Thus, knockdown of AMPK prevented berberine-
induced phosphorylation of the AMPK substrates ACC at Ser79 and Raptor at
Ser792 when added at either at 3 mM or 6 mM. Consequently, berberine hampered
mTORC1 and ERK activation through AMPK signaling at low doses but at higher
concentrations, berberine inhibited mitogenic signaling, at least in part, through
an AMPK-independent pathway in PDAC cells.
In accord with this conclusion, knockdown of a1 and a2 catalytic subunit
expression of AMPK substantially prevented the inhibitory effect produced by low
doses of berberine on the stimulation of DNA synthesis in PDAC cells (Fig. 5, C).
In contrast, at higher concentrations, berberine inhibited DNA synthesis through
an AMPK-independent mechanism. These results reinforce the notion that
berberine inhibits mitogenic signaling in PDAC cells through distinct AMPK-
dependent and independent mechanisms in a dose-dependent manner.
The quantification of the immune signals was performed using Multi Gauge V3.0. The results are presented in
the plots shown in panels B and D. The values represent the mean ¡ SEM (n53) of S6K, S6 and ERK
phosphorylation expressed as a percentage of the maximal response obtained in 3 independent experiments.
doi:10.1371/journal.pone.0114573.g004
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Previously, we demonstrated that metformin, at low concentrations, inhibited
DNA synthesis through an AMPK-dependent mechanism in PANC-1 cells
incubated in medium containing physiological concentrations of glucose [44].
The results obtained here with berberine prompted us to examine further the
notion that inhibitors of mitochondrial function impede mitogenic signaling
through AMPK-dependent and independent mechanisms in a dose-dependent
manner. Knockdown of a1 and a2 catalytic subunit expression of AMPK
prevented the increase in the phosphorylation of ACC at Ser79 and Raptor at
Ser792 in cells treated with metformin at either 1 mM or 3 mM (Fig. 6 A;
Fig. 5. Knockdown of the a subunits of AMPK reverses inhibition of mTORC1, ERK and DNA synthesis induced by low but not high doses of
berberine. A, PANC-1 cells were transfected with either non-targeting negative control (Non Target.) or 10 nM AMPKa1 and 10 nM AMPKa2 siRNA
(AMPKa1, a2 siRNA) in DMEM containing 5 mM glucose and 10% FBS. After 3 days the cells were incubated either in the absence or presence of berberine
for 17 h in serum free DMEM containing 5 mM glucose. Then, the cells were stimulated for 1 h with 5 nM neurotensin and 10 ng/ml insulin and lysed with 2X
SDS-PAGE sample buffer. The samples were analyzed by SDS-PAGE and immunoblotting with the following phospho antibodies: S6K at Thr389, S6 at
Ser240/244, and ERK at Thr202 and Tyr204, ACC at Ser79 and Raptor at Ser792. Shown here is a representative autoluminogram; similar results were obtained
in 4 independent experiments. B, Quantification was performed using Multi Gauge V3.0. Results are expressed as the percentage of the maximum (mean
¡SEM: n54). C, PANC-1 cells were transfected with either non-targeting negative control (open bars) or 10 nM AMPKa1 and 10 nM AMPKa2 siRNA (black
bars) in DMEM containing 5 mM glucose and 10% FBS. After 3 days the cells were incubated for 6 h in serum-free medium containing 5 mM glucose. Then,
5 nM neurotensin and 10 ng/ml insulin and the indicated concentration of berberine were added for 17 h at 37˚C prior to the addition of [3H]-thymidine for
6 h. The radioactivity incorporated into acid-insoluble pools was measured in a scintillation counter, as described in ‘‘Materials and Methods’’. Results are
expressed as the percentage of maximum mean ¡ SEM obtained in 4 independent experiments (3 replicate cultures per point in each experiment).
doi:10.1371/journal.pone.0114573.g005
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quantification in Fig. 6, B). Interestingly, siRNA-mediated depletion of AMPK
reversed the inhibitory effect produced by 1mM metformin on mTORC1 (scored
by phosphorylation of S6K at Thr389 and of its substrate S6) and ERK activation in
PDAC cells (Fig. 6 A; quantification in Fig. 6, B). In contrast, knockdown of
AMPK did not prevent the inhibitory effect of metformin on mTORC1 and ERK
when added at 3 mM (Fig. 6 A; quantification in Fig. 6, B). Furthermore,
knockdown of a1 and a2 catalytic subunit expression of AMPK substantially
Fig. 6. Knockdown of the a subunits of AMPK reverses inhibition of mTORC1, ERK and DNA synthesis induced by low doses of metformin. A,
PANC-1 cells were transfected with either non-targeting negative control (Non Target.) or 10 nM AMPKa1 and 10 nM AMPKa2 siRNA (AMPKa1, a2 siRNA)
in DMEM containing 5 mM glucose and 10% FBS. After 3 days the cells were incubated either in the absence or presence of 1 mM or 3 mM metformin (as
indicated) for 17 h in serum free DMEM containing 5 mM glucose. The samples were analyzed by SDS-PAGE and immunoblotting with the following
phospho antibodies: S6K at Thr389, S6 at Ser240/244, ERK at Thr202 and Tyr204, ACC at Ser79 and Raptor at Ser792 Shown here is a representative
autoluminogram; similar results were obtained in 3 independent experiments. B, Quantification was performed using Multi Gauge V3.0. Results are
expressed as the percentage of maximum (mean¡SEM; n53). C, PANC-1 cells were transfected with either non-targeting negative control (open bars) or
10 nM AMPKa1 and 10 nM AMPKa2 siRNA (black bars) in DMEM containing 3 mM glucose and 10% FBS. After 3 days the cells were incubated for 6 h in
serum-free medium containing 5 mM glucose. Then, 5 nM neurotensin and 10 ng/ml insulin and metformin at either 1 mM or 3 mM were added for 17 h at
37˚C prior to the addition of [3H]-thymidine for 6 h. The radioactivity incorporated into acid-insoluble pools was measured in a scintillation counter, as
described in ‘‘Materials and Methods’’. Results are expressed as the percentage of maximum mean ¡SEM obtained in 3 independent experiments (3
replicate cultures per point in each experiment).
doi:10.1371/journal.pone.0114573.g006
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reversed the inhibitory effect produced by 1 mM metformin on the stimulation of
DNA synthesis in PDAC cells but did not prevent inhibition of DNA synthesis
produced by 3 mM metformin. Collectively, these results support the notion that
structurally unrelated inhibitors of mitochondrial function, including berberine
and metformin, inhibit mitogenic signaling in PDAC cells through AMPK-
dependent and independent mechanisms in a dose-dependent manner.
To substantiate the operation of AMPK-mediated inhibition of mitogenic
signaling in pancreatic cancer cells, we determined whether treatment with A-
769662, a direct AMPK agonist [78, 79], inhibits mTORC1 and DNA synthesis in
PANC-1 cells. As expected for a compound that acts directly on AMPK rather
than through inhibition of mitochondrial function, A-769662 neither reduced
mitochondrial membrane potential nor decreased ATP levels in PANC-1 cells but
induced robust phosphorylation of ACC at Ser79 and Raptor at Ser792 (S2 Figure).
At the concentrations used, A-769662 inhibited mTORC1-mediated phosphor-
ylation of S6K at Thr389 and of S6 at Ser240/244 and DNA synthesis in PANC-1 cells
(S2 Figure). The results corroborate that AMPK activation inhibits mitogenic
signaling in pancreatic cancer cells.
Discussion
The studies presented here were designed to explore the hypothesis that
structurally unrelated natural or synthetic compounds that interfere with
mitochondrial-mediated ATP synthesis and target mTORC1 and ERK pathways,
provide novel anti-PDAC agents. Our results demonstrate that treatment of
pancreatic cancer PANC-1 and MiaPaCa-2 cells with berberine potently inhibited
DNA synthesis, cell cycle progression and proliferation in a dose-dependent
manner. We noticed that most previous studies examining effects of berberine
in vitro were carried out with cancer cells cultured in medium supplemented with
supra-physiological concentrations of glucose (e.g. 25 mM, as in DMEM) and
used berberine at doses as high as 50 mM [61, 80, 81]. When PDAC cells were
cultured in medium containing a physiological concentration of glucose, as in this
study, berberine induced growth-suppressive effects at a dose as low as 1.5–3 mM.
In view of the inhibitory effects of berberine on the proliferative responses of
PDAC cells in vitro, we examined whether this compound inhibits pancreatic
cancer growth using the MiaPaca-2 tumor xenograft model in nude mice. Our
results show that administration of berberine markedly inhibited the growth of
human pancreatic cancer cells xenografted into nude mice, as effectively as
metformin. Given that berberine inhibited PDAC cell proliferation both in vitro
and in vivo, it was important to elucidate its mechanism of inhibitory action in
these cells.
Berberine has been proposed to inhibit complex I of the mitochondrial
respiratory chain, reduce ATP synthesis and thereby activate AMPK, a highly
conserved sensor of cellular energy being activated when ATP concentrations
decrease and 59-AMP concentrations increase [73]. Accordingly, we demonstrate
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here that exposure of PDAC cells to berberine decreased mitochondrial
membrane potential and induced a marked, dose-dependent decline in the
intracellular levels of ATP. Concomitantly, berberine produced a pronounced
dose-dependent stimulation of AMPK, as judged by the increase in the
phosphorylation of ACC at Ser79, a reliable biomarker of AMPK activity within
intact cells [75] and phosphorylation Raptor at Ser792. AMPK has been proposed
to inhibit mTORC1 activation by phosphorylation of TSC2 [40–42], Raptor [82]
and IRS-1 [83, 84]. Accordingly, we demonstrate here that berberine inhibited
mTORC1 activity in PDAC cells, as shown by monitoring the phosphorylated
state of S6K at Thr389, a residue directly phosphorylated by mTORC1 and the
phosphorylation of S6, a downstream target of S6K [77]. Furthermore, berberine
also inhibited ERK activation in PDAC cells. The inhibitory effects of berberine on
mTORC1 and ERK were elicited at doses that hampered mitochondrial function,
reduced intracellular levels of ATP and activated AMPK within intact PDAC cells.
Although the preceding results are consistent with the notion that AMPK
mediates some of the inhibitory effects of berberine on mitogenic signaling in
PDAC cell, the precise role of AMPK in the proliferation and survival of cancer
cells has become controversial [85]. Specifically, it remains unclear whether
AMPK suppresses cancer cell proliferation (tumor suppressive function) or
alternatively enhances cancer cell survival under conditions of metabolic stress
(tumor promoter function). A tumor suppressive activity of AMPK is strongly
implicated in Myc-induced lymphomagenesis [86], aerobic glycolysis [86] and in
the mechanism underlying the gain of oncogenic function of certain p53 protein
mutants [87]. Conversely, several recent reports have also shown that AMPK
promotes tumorigenesis via protecting cancer cell viability under energy stress
conditions [88] and enhances metabolic transformation [89]. These contrasting
views prompted us to determine the role of AMPK in human pancreatic cancer
cells. Specifically, we examined whether knockdown of the protein expression of
both a1 and a2 catalytic subunits of AMPK in these cells opposes or facilitates the
inhibitory effects induced by berberine and metformin, two agents that induce
metabolic stress via inhibition of mitochondrial function and interference with
ATP synthesis.
Our results led us to propose a novel mechanism of action for these agents that
is sharply dependent on the dose used. We found that knockdown of the a
subunits of AMPK reversed the inhibition of mTORC1 and ERK induced by low
doses of berberine. Consequently, we propose that berberine inhibits mitogenic
signaling through an AMPK-dependent pathway when used at low concentrations
and in PDAC cells cultured in physiological concentration of ambient glucose.
However, at higher concentrations, berberine inhibited mitogenic signaling
(mTORC1 and ERK) and DNA synthesis through an AMPK-independent
mechanism. Importantly, AMPK knockdown prevented the increase in the
phosphorylation of ACC at Ser79 and Raptor at Ser792 induced by berberine at
either low or high doses.
A number of studies, using high concentrations of metformin (e.g. 10 mM, as
in [39, 90]) indicated that the inhibitory effect of metformin on mTORC1 is not
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dependent on AMPK but the significance of results obtained with metformin at
such high doses has been questioned. The results presented here with berberine
prompted us to examine the generality of the notion that inhibitors of
mitochondrial function, including metformin, hinder mitogenic signaling
through AMPK-dependent and independent mechanisms in a dose-dependent
manner. We found that metformin inhibited mitogenic signaling (mTORC1, ERK
and DNA synthesis) through an AMPK-dependent pathway when used at 1 mM
and in PDAC cells cultured in physiological concentration of ambient glucose
(5 mM). In this context, it will be of interest to examine whether berberine and
metformin display synergistic effects with other molecules that act directly on
AMPK, including A-769662 [91, 92]. However, at higher concentrations,
metformin inhibited mitogenic signaling and DNA synthesis through an AMPK-
independent mechanism. In support of this conclusion, AMPK knockdown
prevented the increase in the phosphorylation of ACC at Ser79 and Raptor at
Ser792 induced by metformin at either low or high doses. Remarkably, these results
were obtained with metformin used at doses that induced either modest or
pronounced declines in intracellular ATP levels, which were virtually identical to
the decreases in ATP levels obtained in response to berberine (Fig. 3 B). It is
plausible that the decline in ATP levels produced by higher doses of either
berberine or metformin interferes with ATP-consuming processes required for
anabolic metabolism and cell proliferation in an AMPK-independent manner. We
therefore propose that berberine and metformin inhibit mitogenic signaling in
PDAC cells through an AMPK-dependent pathway at low concentrations but act
via AMPK-independent pathways in the same cells when added at higher doses.
This conclusion provides a plausible explanation for apparently contradictory
reports on the role of AMPK in the mechanism of action of berberine and
metformin in other model systems and emphasizes the need of using detailed
dose-response studies to define the anticancer mechanisms of action of agents that
produce metabolic stress via inhibition of mitochondrial function.
In conclusion, our results raise the attractive possibility that treatment with
berberine, a widely used agent used in traditional medicine, directly inhibits
pancreatic cancer cell proliferation. Our mechanistic studies with berberine and
metformin provide evidence in favor of a dose-dependent tumor suppressive role
of AMPK in PDAC cells and offer the bases for novel therapeutic strategies for the
treatment of pancreatic cancer, a devastating disease with limited survival option.
Supporting Information
S1 Figure. Berberine inhibits mTORC1 signaling and ERK activation in PDAC
cells stimulated with fetal bovine serum (FBS). Cultures of PANC-1 cells were
incubated in the absence or in the presence of increasing concentrations of
berberine. Then, the cells were stimulated for 1 h with 2.5% FBS and lysed with
2X SDS-PAGE sample buffer. The samples were analyzed by SDS-PAGE and
immunoblotting with antibodies that detect the phosphorylated state of S6K at
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Thr389, S6 at Ser240/244, and ERK at Thr202 and Tyr204. Immunoblotting with total
S6K, S6 and ERK was used to verify equal gel loading.
doi:10.1371/journal.pone.0114573.s001 (PDF)
S2 Figure. A769662 inhibits mTORC1 signaling and DNA synthesis in PANC-1
cells. A) Cells were incubated without or with 50 mM A769662 or 1 mM
metformin and stimulated with 5 nM neurotensin (NT) and 10 ng/ml insulin
(Ins). Lysates were analyzed by SDS-PAGE and immunoblotting with antibodies
that detect the phosphorylated state of ACC at Ser79, Raptor at Ser792, S6K at
Thr389 and S6 at Ser240/244. Irrelevant lanes in the original autoradiograph were
removed and relevant ones yuxtaposed (indicated by the vertical line). B)
A769662 (50 mM) does affect mitochondrial membrane potential (fluorescence
ratio) measured with JC-1 or reduces ATP levels. C Dose-dependent inhibition of
[3H]-thymidine incorporation into DNA by increasing concentrations of A769662
in PANC-1 cells stimulated with neurotensin and insulin. Image Editing:
Irrelevant lanes were removed (indicated by a thin, vertical black line) from the
acquired digital images and flanking lanes juxtaposed using Adobe Photoshop.
doi:10.1371/journal.pone.0114573.s002 (PDF)
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